Selecting Treatment for BCG-Unresponsive NMIBC

Panelists discuss how for patients with BCG-unresponsive bladder cancer, treatment selection depends on key factors including tumor characteristics (carcinoma in situ vs papillary), patient fitness, and preferences. Standard options include radical cystectomy (the gold standard) or bladder-preserving approaches such as pembrolizumab, intravesical chemotherapy, or clinical trials. The decision requires careful individualization based on risk stratification, comorbidities, and shared decision-making.

EP: 1.Standard of Care in NMIBC

EP: 2.BCG-Unresponsive NMIBC and Treatments

EP: 3.Recent FDA Approvals in NMIBC

Now Viewing

EP: 4.Selecting Treatment for BCG-Unresponsive NMIBC

Video content above is prompted by the following:

• How do you decide which therapy to use in patients with BCG-unresponsive disease?

Related Videos

Related Content

Advertisement

February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 29th 2025

UTUC roundtable discussions highlight guidelines, patient cases

Urology Times staff

Two recent roundtable discussions focused on the challenges and evolving treatment strategies in upper tract urothelial carcinoma.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 27th 2025

Anktiva under review in EU for BCG-unresponsive NMIBC with CIS

Hannah Clarke

If approved, the marketing authorization application would be valid in all 27 European Union member states as well as in Iceland, Liechtenstein, and Norway.

January 22nd 2025

UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma

Hannah Clarke

"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.

Related Content

Advertisement

February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 29th 2025

UTUC roundtable discussions highlight guidelines, patient cases

Urology Times staff

Two recent roundtable discussions focused on the challenges and evolving treatment strategies in upper tract urothelial carcinoma.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 27th 2025

Anktiva under review in EU for BCG-unresponsive NMIBC with CIS

Hannah Clarke

If approved, the marketing authorization application would be valid in all 27 European Union member states as well as in Iceland, Liechtenstein, and Norway.

January 22nd 2025

UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma

Hannah Clarke

"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.